Sepsis is a systemic inflammatory response to a confirmed or suspected infection. The transition from sepsis to septic shock causes high rate of mortality. The aim of this experiment was to evaluate the anti-inflammatory potential of the Biofield Energy Treated Proprietary Test Formulation and Biofield Energy Treatment per se to the animals on Cecal Slurry, LPS and E. coli-induced systemic inflammatory response syndrome (SIRS) model in Sprague Dawley rats using serum inflammatory biomarkers. In this experiment, various inflammatory biomarkers such as C-reactive protein (CRP), leptin, nitric oxide (NO), substance polypeptide (substance P), matrix metalloproteinase-2 (MMP-2), and monocyte chemoattractant protein-1 (MCP-1) were analysed using ELISA assay. A test formulation was formulated including minerals (magnesium, zinc, calcium, selenium, and iron), vitamins (ascorbic acid, pyridoxine HCl, vitamin E, cyanocobalamin, and cholecalciferol), Panax ginseng extract, β-carotene, and cannabidiol isolate. The constituents of the test formulation were divided into two parts; one section was defined as the untreated test formulation, while the other portion of the test formulation and three group of animals received Biofield Energy Healing Treatment remotely for about 3 minutes by a renowned Biofield Energy Healer, Mr. Mahendra Kumar Trivedi. The results showed that the level of CRP was significantly (p≤0.001) reduced by 36.78%, 37.67%, 34.44%, 61.70%, and 43.37% in the G5 (Cecal Slurry, LPS and E. coli along with the Biofield Energy Treated test formulation); G6 (Cecal Slurry, LPS and E. coli along with Biofield Energy Treatment per se to animals from day -15); G7 (Cecal Slurry, LPS and E. coli along with the Biofield Energy Treated test formulation from day -15); G8 (Cecal Slurry, LPS and E. coli along with Biofield Energy Treatment per se plus the Biofield Energy Treated test formulation from day -15), and G9 (Cecal Slurry, LPS and E. coli along with Biofield Energy Treatment per se animals plus the untreated test formulation) groups, respectively as compared to the disease control (G2) group. Additionally, the level of leptin was significantly increased by 11.83% and 16.48% (p≤0.05) in the G5 and G7 groups, respectively as compared to the G2 group. The level of NO was increased by 25.97% in the G6 group as compared to the G2 group. The level of substance P was significantly decreased by 32.62% (p≤0.001), 11.89%, 30.5% (p≤0.001), 11.21%, and 15.64% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. Moreover, the level of MMP-2 was significantly decreased by 17.35% (p≤0.05) and 42.98% (p≤0.001) in the G8 and G9 groups, respectively as compared to the G2 group; while 28.43%, 50.62%, and 22.43% decreased in the G6, G8, and G9 groups, respectively as compared to the untreated test formulation group (G4). Additionally, the level of MCP-1 was significantly (p≤0.001) decreased by 53.42%, 53.47%, 55.30%, 54.58%, and 53.88% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. Overall, the data suggested anti-inflammatory potentials of the Biofield Energy Treated test formulation and Biofield Energy Treatment per se along with preventive measure on the animal with respect to various inflammatory conditions that might be beneficial various types of systemic inflammatory disorders specially sepsis, trauma, septic shock or any types of injuries. Therefore, the results showed the significant slowdown the inflammation-related disease progression and its complications/symptoms in the preventive Biofield Energy Treatment group per se and/or Biofield Energy Treated Test formulation groups (viz. G6, G7, G8, and G9) comparatively with the disease control group.
